What if it's more complex than just doing a straight forward deal?
What if they first have to work out what the FDA is happy with and what they aren't. What are the new protocols that are acceptable, what is monitoring and tracking requirements and indeed as a result, what is the cost!
Once we have this we can chat further with funding parties. But even that will take some time in my mind.
There may not just be one party...there may be new parities, there may be all sorts of entities. Some will be serious, some maybe not so...some will have strengths for us that we need....others will pay better royalties...and if that's not enough, some are regional experts...depending on the region!
This will take some time.
I am more on the optimistic side, you may have guessed that, it maybe hasn't done me so good so far...but maybe it has! If nothing else (other than frustration, some degree of flak and a bit more frustration and tying up some cash...ok a fair bit of cash)....it has allowed me to buy more cheaper.
Not advice.
Let's wait for this imminent news.
.
- Forums
- ASX - By Stock
- PAR
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-75
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 143324 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 44935 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 138349 | 0.200 |
9 | 191984 | 0.195 |
15 | 199884 | 0.190 |
6 | 161140 | 0.185 |
16 | 784128 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 44935 | 3 |
0.215 | 132157 | 4 |
0.220 | 82155 | 7 |
0.225 | 31604 | 3 |
0.230 | 33834 | 4 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
NEWS
New gold and silver soil anomalies uncovered at Black Range, strengthening exploration potential
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online